Title {1}	Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9% saline on delayed graft function in deceased donor kidney transplantation.
Trial registration {2a and 2b}	Australian New Zealand Clinical Trials Registry ACTRN12617000358347 ClinicalTrials.gov identifier NCT03829488
Protocol version {3}	Version 3.1, 2 March 2020
Funding {4}	1. Medical Research Future Fund (MRFF) Rare Cancers, Rare Diseases and Unmet Needs Grant 2018 (APP1152390) 2. Health Research Council of New Zealand Project Grant 2017 (17/414) 3. Better Evidence And Translation in Chronic Kidney Disease (BEAT-CKD) grants 2016 and 2017 (from NHMRC program grant 2014 APP1092957, Chief Investigator Jonathan Craig) 4. Royal Australasian College of Physicians Jacquot Research Establishment Fellowship grants 2017 and 2018 (awarded to Dr. Michael Collins) 5. Baxter Investigator Initiated Research Grant (Medication Delivery) 2017 (in kind support; provision of trial fluids)
Author details {5a}	1. Department of Renal Medicine, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand 2. Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand 3. Australasian Kidney Trials Network, The University of Queensland, Brisbane, Australia 4. Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia 5. Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia 6. Department of Medicine, The University of Adelaide, Adelaide, Australia 7. Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia 8. Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia 9. Department of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand 10. Department of Nephrology, Austin Health, Melbourne, Australia 11. Department of Medicine (Austin), The University of Melbourne, Parkville, Melbourne, Australia 12. Department of Anaesthesia, Austin Health, Melbourne, Australia 13. The University of Melbourne, Department of Surgery, Austin Health, Melbourne, Australia 14. Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia 15. Charles Perkins Centre, The University of Sydney, Sydney, Australia * Correspondence: Dr. Michael G. Collins, FRACP, PhD, Department of Renal Medicine, Auckland District Health Board, Private Bag 92,024, Auckland 1142, New Zealand Email: michael.collins@adhb.govt.nz
Name and contact information for the trial sponsor {5b}	The University of Queensland acting through Australasian Kidney Trials Network (AKTN) Email: aktn@uq.edu.au
Role of sponsor {5c}	The sponsor is the coordinating center for the trial and is involved in overall study activities including study design, collection, management, analysis and interpretation of data, writing of the report, and decision to submit the report for publication. Baxter Healthcare will be provided with the report for review. Neither Baxter Healthcare nor the other funders have any involvement in the design, oversight, data collection, analysis, interpretation, or reporting of the study, or the decision to submit the report for publication.